AP8

AP8
Identifiers
	IUPAC name (2S,3R)-3-cyclopropyl-3-[(2R)-2-[1-[(1S)-1-[5-fluoro-2-(trifluoromethoxy)phenyl]ethyl]piperidin-4-yl]-3,4-dihydro-2H-chromen-7-yl]-2-methylpropanoic acid;
PubChem CID	127053597;
ChemSpider	61712481;
Chemical and physical data
Formula	C30H35F4NO4
Molar mass	549.607 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H](C1=C(C=CC(=C1)F)OC(F)(F)F)N2CCC(CC2)[C@H]3CCC4=C(O3)C=C(C=C4)[C@H](C5CC5)[C@H](C)C(=O)O;
	InChI InChI=1S/C30H35F4NO4/c1-17(29(36)37)28(21-4-5-21)22-6-3-19-7-9-25(38-27(19)15-22)20-11-13-35(14-12-20)18(2)24-16-23(31)8-10-26(24)39-30(32,33)34/h3,6,8,10,15-18,20-21,25,28H,4-5,7,9,11-14H2,1-2H3,(H,36,37)/t17-,18-,25+,28-/m0/s1; Key:ADYYYLTWZYYGNX-LJYIQKJHSA-N;

AP8 is an experimental drug which acts as a selective agonist for the free fatty acid receptor FFAR1 (GPR40). It has antiinflammatory and anti-fibrotic effects.^[1]^[2]^[3]

References

↑ Lu J, Byrne N, Wang J, Bricogne G, Brown FK, Chobanian HR, et al. (July 2017). "Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40". Nature Structural & Molecular Biology. 24 (7): 570–577. doi:10.1038/nsmb.3417. PMID 28581512.
↑ Atanasio S, Deganutti G, Reynolds CA (November 2020). "Addressing free fatty acid receptor 1 (FFAR1) activation using supervised molecular dynamics". Journal of Computer-aided Molecular Design. 34 (11): 1181–1193. Bibcode:2020JCAMD..34.1181A. doi:10.1007/s10822-020-00338-6. PMID 32851580.
↑ An X, Bai Q, Bing Z, Liu H, Yao X (2021). "Insights into the molecular mechanism of positive cooperativity between partial agonist MK-8666 and full allosteric agonist AP8 of hGPR40 by Gaussian accelerated molecular dynamics (GaMD) simulations". Computational and Structural Biotechnology Journal. 19: 3978–3989. doi:10.1016/j.csbj.2021.07.008. PMC 8313488. PMID 34377364.

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by adding missing information.